| Budget Amount *help |
¥47,970,000 (Direct Cost: ¥36,900,000、Indirect Cost: ¥11,070,000)
Fiscal Year 2015: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2014: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2013: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2012: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2011: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
|---|
| Outline of Final Research Achievements |
Antiplatelet drugs are used for the treatment and secondary prevention of atherothrombosis, while anticoagulant drugs are indicated for deep vein thrombosis, pulmonary thromboembolism, and atrial fibrillation. This study aimed for comprehensive exploration and development of new diagnostic markers specific for antithrombotic therapies.
For antiplatelet therapy, cerebrovascular disease, coronary artery disease, and thrombosis prevention in perioperative phases (including patch closure of ASD using clopidogrel) were investigated. PFA-100, VerfyNow, and T-TAS were shown to be effective.
For anticoagulation therapy, novel diagnostic strategies for new oral anticoagulants (NOACs) were examined. Coagulation studies vary significantly between reagents, which should always be taken into consideration when results were interpreted.
|
